Tuberculosis Clinical Trial
Official title:
Investigation of a Novel Approach to Improve Adherence to Treatment and Treatment Success Rates for Tuberculosis Patients in Senegal
Verified date | December 2006 |
Source | Institut de Recherche pour le Developpement |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Interventional |
Tuberculosis (TB) patients who receive inadequate treatment or do not complete therapy are
more likely to remain infectious, thus contributing to the continuous spread of TB infection
in communities. Despite the widespread use of Directly Observed Therapy, defaulters remain
an important problem in TB control programmes. In Sénégal, defaulters rate reach 30%, which
is hampering dramatically the effectiveness of control. New strategies to deliver treatment
to TB patients and ensure proper adherence that are adapted to the local situations are
urgently needed.
Objectives
The overall objective of the project is to improve tuberculosis treatment success rates in
Sénégal. The specific objectives are:
1. to assess the current situation of tuberculosis (TB) in Sénégal
2. to identify the determinants of cure,
3. to develop measures to improve patient’s compliance with the treatment that are adapted
to the local situation, acceptable, affordable and sustainable
4. to evaluate the impact of these measures on TB control.
Methods
The proposed research seeks to develop and test innovative methods to improve cure rates in
TB patients. It will explore the factors of success of TB treatment using inter-disciplinary
approach, integrating social sciences and economic analyses into TB research. The project is
composed of 3 comprehensive phases:
- Phase 1: baseline assessment of the TB situation.
- Phase 2: anthropological study, investigating various domains contributing to patients
cure using a range of qualitative research methods. At the end of this investigation,
it is expected that determinants of care will be clearly identified. On this basis,
suitable methods for improving patients’ adherence to treatment will be tailored and
developed.
- Phase 3: these methods will be tested and compared using a cluster randomised
controlled trial design, in populations served by defined health centres. Their
efficacy will be measured in terms of improvement of the classical TB control programme
indicators (cure rate, defaulter rate, failure rate, death rates). The methods will
also be evaluated on their acceptability by the TB patients and the communities and on
their feasibility (duration : 24 months).
Expected results:
Methods to improve patients’ adherence to treatment that are affordable, acceptable and
sustainable will be developed and tested according to qualitative and quantitative criteria.
Status | Completed |
Enrollment | 1500 |
Est. completion date | January 2005 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 15 Years to 65 Years |
Eligibility |
Inclusion Criteria: - newly diagnosed sputum-smear positive pulmonary TB (at least two positive specimens), aged 15 years or more, and living in the district served by the District Health Centre. Exclusion Criteria: - Smear-negative tuberculosis cases - extra-pulmonary tuberculosis cases - TB re-treatment cases |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Senegal | Programme National de Lutte Anti-tuberculeuse | Dakar |
Lead Sponsor | Collaborator |
---|---|
Institut de Recherche pour le Developpement |
Senegal,
Lienhardt C, Ogden JA. Tuberculosis control in resource-poor countries: have we reached the limits of the universal paradigm? Trop Med Int Health. 2004 Jul;9(7):833-41. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | TB treatment success rate (cure + completed treatment) | |||
Primary | Treatment defaulting rates | |||
Secondary | treatment failure rate | |||
Secondary | death rate |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |